<DOC>
	<DOCNO>NCT02304705</DOCNO>
	<brief_summary>The purpose study determine whether Sildenafil 20mg take three time day effective treatment Heart Failure Reactive Pulmonary Hypertension . This double-blind , placebo control trial .</brief_summary>
	<brief_title>Sildenafil Heart Failure With Reactive Pulmonary Hypertension</brief_title>
	<detailed_description>Patients screen time diagnositic Right Heart Catheterization . Patients select base pressure measure procedure , current medication , current symptom . At baseline 6 minute walk test quality life questionnaire administer . Medical record review result recent test record . Qualifying participant randomize receive 90 day either placebo sildenafil 20 mg three time day . Randomized patient follow safety efficacy phone otherwise clinically indicate . At end 90 day treatment period , patient evaluate via 6 minute walk , quality life questionnaire , diagnostic test clinically indicate . Primary outcome change 6 minute walk distance . Secondary outcome base clinically available result change heart pressure measure right heart catheterization echocardiogram . At end treatment period , provider patient unblinded order optimize treatment . To achieve statistical significance , 64 patient enrol randomize .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Known chronic heart failure appropriately treat ACE inhibitor beta blocker , unless contraindicate poorly tolerate indication right heart catheterization pulmonary artery mean pressure &gt; 25 mmHg pulmonary capillary wedge pressure &gt; 15 mmHg pulmonary vascular resistance &gt; 3 WU hypersensitivity , allergy , intolerable side effect sildenafil history primary pulmonary hypertension , connective tissue disorder , severe COPD , pulmonary embolism , leave right shunt comorbidities , limited exercise intolerance : morbid obesity ( BMI &gt; 40 ) COPD oxygen dependence severe peripheral vascular disease intermittent claudication status post amputation low extremity level severe degenerative joint disease prevent normal walking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>